• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Needham reiterated coverage on Selecta Biosciences with a new price target

    11/1/21 6:22:33 AM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email
    Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously
    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Selecta Biosciences Inc.

      DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 5:27:24 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Selecta Biosciences Inc.

      DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 4:42:00 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Selecta Biosciences Inc.

      PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      1/31/24 4:30:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Selecta Biosciences downgraded by SVB Securities with a new price target

      SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00

      8/18/23 7:37:44 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Selecta Biosciences with a new price target

      Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously

      6/14/22 7:48:06 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Selecta Biosciences with a new price target

      SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00

      6/6/22 7:48:05 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care